NitricGen had been developing a novel gaseous nitric oxide delivery system - designated the eNOGenerator - for the treatment of slow or difficult to heal wounds. The company initially targeted the market for treatment of chronic diabetic foot ulcers. However, the eNOGenerator is a platform technology that could potentially be modified to treat other chronic wounds such as pressure and venous ulcers and potentially numerous other conditions as the promise of gaseous nitric oxide therapy is further researched and applied to other medical conditions. In a deal finalized in January 2018, AIT Therapeutics Inc. (OTC:AITB), -- a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension - entered into a letter of intent to acquire worldwide exclusive transferable rights to NitricGen Inc.'s eNOGenerator and related intellectual property.
